Biomarker Development for Diabetic Complications (R21)

The summary for the Biomarker Development for Diabetic Complications (R21) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Biomarker Development for Diabetic Complications (R21): Type 1 diabetes is a metabolic disorder in which hyperglycemia and other metabolic defects lead to significant morbidity and mortality through cardiovascular disease, stroke, chronic renal failure, blindness, nerve impairment and amputations. Better assessments of disease progression are needed for patient care and the development of therapeutics. This FOA seeks R21 grant applications for exploratory and developmental research on biomarkers for the microvascular and macrovascular complications of diabetes. -This Funding Opportunity Announcement (FOA) will utilize the R21 grant mechanism. -The participating organizations intend to commit a total of $3 million to this FOA for payment of applications responsive to this announcement. -Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. -Eight to twelve awards are anticipated. -Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and costs of the applications received. -Project Period and Award Amounts: In most cases, an applicant may request a project period of up to 2 years and a total budget for direct costs up to $300,000 for the entire project. Applicants may request a project period of up to 3 years and a total of $600,000 in direct costs with budgets not exceeding $250,000 in any one year for clinical studies involving expensive imaging studies or measurements on a large number of stored clinical specimens. -Eligible organizations: For profit organizations; Non-profit organizations; Public or private institutions, such as universities, colleges, hospitals and laboratories; Units of State government; Units of local government; Eligible institutions of the Federal government; Domestic institutions; Foreign institutions. -Eligible Project Directors/Principal Investigators (PD/PIs): Any individual with the skills, knowledge, and resources necessary to carry out the proposed research is invited to work with their institution to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. -Applicants may submit more than one application, provided each application is scientifically distinct.
Federal Grant Title: Biomarker Development for Diabetic Complications (R21)
Federal Agency Name: National Institutes of Health
Grant Categories: Health
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-DK-06-004
Type of Funding: Grant
CFDA Numbers: 93.83793.847
CFDA Descriptions: Heart and Vascular Diseases Research 93.847 Diabetes, Endocrinology and Metabolism Research
Current Application Deadline: No deadline provided
Original Application Deadline: Dec 13, 2006
Posted Date: Apr 19, 2006
Creation Date: Apr 19, 2006
Archive Date: Jan 12, 2007
Total Program Funding: $3,000,000
Maximum Federal Grant Award: $250,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: 93.867 -- Vision Research
Applicants Eligible for this Grant
County governments Native American tribal governments (Federally recognized) For profit organizations other than small businesses Private institutions of higher education State governments Native American tribal organizations (other than Federally recognized tribal governments) Public housing authorities/Indian housing authorities City or township governments Independent school districts Others (see text field entitled "Additional Information on Eligibility" for clarification) Special district governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education
Additional Information on Eligibility
Foreign institutions are eligible to apply. Eligible agencies of the Federal Government can apply.
Link to Full Grant Announcement
Information not provided
Grant Announcement Contact
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV
FBOWebmaster@OD.NIH.GOV If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
More Grants from the National Institutes of Health
Implementation Science for Cancer Control: Developing Centers (P50 Clinical Trial Optional...
Medications Development for the Treatment of Alcohol Use Disorder (U01 Clinical Trial Opti...
Enabling Technologies to Accelerate Development of Oral Biodevices (R01 Clinical Trial Not...
Enabling Technologies to Accelerate Development of Oral Biodevices (R21 Clinical Trial Not...
Implementation Science for Cancer Control: Advanced Centers (P50 Clinical Trial Optional)

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2018 FederalGrants.com